FASEB J. Thermo Fisher Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WATTANAPITAYAKUL, S. K.
Right arrow Articles by BAUER, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WATTANAPITAYAKUL, S. K.
Right arrow Articles by BAUER, J. A.
(The FASEB Journal. 2000;14:271-278.)
© 2000 FASEB

Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders

SUVARA KIMNITE WATTANAPITAYAKUL, DAVID M. WEINSTEIN, BETHANY J. HOLYCROSS and JOHN ANTHONY BAUER1

Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus Ohio, 43210, USA. E-mail: Bauer.140{at}osu.edu

1Correspondence: Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus OH, 43210, USA. E-mail: Bauer.140{at}osu.edu


   ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Angiotensin II (ANG II) is a well-established participant in many cardiovascular disorders, but the mechanisms involved are not clear. Vascular cell experiments suggest that ANG II is a potent stimulator of free radicals such as superoxide anion, an agent known to inactivate nitric oxide and promote the formation of peroxynitrite. Here we hypothesized that ANG II reduces the efficacy of NO-mediated vascular relaxation and promotes vascular peroxynitrite formation in vivo. ANG II was infused in rats at sub-pressor doses for 3 days. Systolic blood pressure and heart rate were unchanged on day 3 despite significant reductions in plasma renin activity. Thoracic aorta was isolated for functional and immunohistochemical evaluations. No difference in isolated vascular contractile responses to KCI (125 mM), phenylephrine, or ANG II was observed between groups. In contrast, relaxant response to acetylcholine (ACh) was decreased sixfold without a change in relaxant response to sodium nitroprusside. Extensive prevalence of 3-nitrotyrosine (3-NT, a stable biomarker of tissue peroxynitrite formation) immunoreactivity was observed in ANG II-treated vascular tissues and was specifically confined to the endothelium. Digital image analysis demonstrated a significant inverse correlation between ACh relaxant response and 3-NT immunoreactivity. These data demonstrate that ANG II selectively modifies vascular NO control at sub-pressor exposures in vivo. Thus, endothelial dysfunction apparently precedes other established ANG II-induced vascular pathologies, and this may be mediated by peroxynitrite formation in vivo. Wattanapitayakul, S., Weinstein, D. M., Holycross, B. J., Bauer, J. A. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders.


Key Words: nitric oxide • vascular • peroxynitrite • endothelium • angiotensin II • oxidation


   INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
ANGIOTENSIN II (ANG II) is a well-recognized participant in many cardiovascular diseases, and its production or activity are currently important targets in cardiovascular pharmacology and medicine (ACE inhibitors and ANG II receptor antagonists) (1 , 2) . Early studies of this hormone demonstrated its potent vasoconstrictive actions, while more recent studies have defined important effects on vascular cell growth, differentiation, and gene expression (3 , 4 , 5) . Recent studies using isolated vascular cells demonstrate that ANG II promotes the production of oxygen radicals (particularly superoxide anion) (6 , 7) , and this may be an important component of ANG II-mediated cardiovascular disease (8 , 9) . Although a role for ANG II in cardiovascular disease is well established, the mechanisms by which it participates have not been elucidated. In particular, the early and initiating events during elevated ANG II levels in vivo are not well defined.

In the last decade, recognition of the importance of vascular endothelial cells for maintenance and regulation of vascular health has emerged (10 , 11) . Nitric oxide (NO) derived from vascular endothelial cells has been shown to be a critical modulator of local vascular tone and thrombus formation; deficient endothelial NO production has been demonstrated in a wide array of cardiovascular diseases including hypertension, atherosclerosis, unstable angina, and congestive heart failure (10 , 11 , 12) . The chemistry of NO in biological matrices is very complex, and several biochemical pathways other than NO production can influence NO actions (13 , 14) . For example, superoxide anion interacts with NO, reduces its efficacy as a signal transduction agent, and promotes the formation of peroxynitrite, a highly reactive intermediate known to nitrate protein tyrosine residues and cause cellular oxidative damage (15 , 16) . The reaction of NO with superoxide anion occurs at a diffusion-limited reaction rate and NO is the only molecule known to compete with superoxide dismutase for its substrate in a biological setting (17 , 18 , 19) . Thus, excess or uncontrolled superoxide anion formation can shift the actions of available NO from a useful cellular signal to peroxynitrite and redox-related toxic products.

While dysfunction of vascular endothelium and elevated blood concentrations of ANG II are each commonly observed in many forms of cardiovascular disease, few studies have evaluated the relationships between these phenomena. Here we investigated the actions of ANG II in vivo, testing the hypotheses that sub-pressor ANG II causes selective vascular dysfunction and that vascular peroxynitrite formation (and attendant dysregulation of NO control) participates in this phenomenon.


   MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Animal model and angiotensin administration
Osmotic mini-pumps (Alza Corp., Palo Alto, Calif.) were used to provide continuous ANG II administration for 3 consecutive days in rats (male Sprague Dawley, 325–350 g). Intraperitoneal implantation was conducted during pentobarbital anesthesia using a sterile surgical technique. ANG II (200 ng·kg-1·min-1) or saline vehicle was administered at a flow rate of 1.0 µl/h. The dose used here has been shown by others to be a ‘slow-pressor dose’ in rats, producing no significant elevation of systemic blood pressure until 7 days of continuous administration (4 , 5) . ANG II was kindly supplied by Bachem Biosciences Inc. (King of Prussia, Pa.). Prior to pump implantation (day 0) and on day 3 of infusion, systemic blood pressure and heart rate were evaluated in conscious rats using a tail cuff apparatus (Stoelting Instruments, Wood Dale, Ill.). After pentobarbital overdose (75 mg/kg i.p.), blood was rapidly collected by cardiac puncture and vascular tissues were rapidly isolated.

Plasma renin activity
Blood was collected by cardiac puncture at death and plasma was rapidly collected. Plasma renin activity was measured by a commercially available radioimmunoassay kit adapted for low-volume samples (Incstar, Stillwater, Minn.). Activity was determined as nanogram of angiotensin I produced per ml/h. Intra-day and inter-day assay variability was less than 10%.

Isolated vascular studies
After animals were killed, the thoracic aorta was rapidly isolated for functional evaluations using methods similar to those previously described (20 , 21) . Vascular segments (2–3 mm) were mounted on isometric force transducers (Grass Instruments, Quincy, Mass.) and incubated in 10 ml organ baths containing Krebs’ buffer bubbled with 95% O2 at 37°C. After 90 min equilibration (resting tone 1.0 g), maximal contractile force was determined for each segment using a high potassium concentration (modified Kreb’s buffer containing 14.4 mM NaCl and 125 mM KCl). This complete depolarization was used to define maximal contractile response and was considered 100% contraction. Segments were then consecutively washed with Krebs’ buffer four times, with two 5 min intervals and two 10 min intervals, and allowed to equilibrate for 30 min. Cumulative responses to cumulative concentrations of phenylephrine were then determined. In parallel studies, in vitro responses to ANG II were evaluated by single exposure of concentrations ranging from 1 nM to 1 µM (thus preventing development of tachyphylaxis).

After precontraction with phenylephrine at 80% of maximum, relaxant responses to cumulative acetylcholine were assessed. In preliminary experiments, acetylcholine relaxation was completely blocked by 200 µM L-nitroarginine (a nonspecific NOS inhibitor); thus, the vasodilatory response is apparently endothelium dependent and NO mediated in this vascular tissue. Relaxant responses to cumulative sodium nitroprusside were also determined (an endothelium independent but NO-mediated response) (22) . Contractile and relaxant response data were fit to the 4-parameter logistic equation using GraphPad Prism Software (GraphPad Software, Inc., San Diego, Calif.) (20 , 21) .

Immunohistochemistry
Immunohistochemistry was performed to determine the relative extent of protein nitration (a stable biomarker of endogenous peroxynitrite formation), using an antibody raised against 3-nitrotyrosine (3-NT). A section of aorta from each rat, separated from the isolated vascular tissue studies, was fixed in formalin and embedded in paraffin. Aorta cross sections were cut into 5 µm sections, deparaffinized, and rehydrated. Tissues were then exposed to a 3% hydrogen peroxide/methanol solution for 10 min to block endogenous peroxidase activity. To restore antigenicity, slides were immersed for 15 min in a 10 mM citrate buffer (pH 6) preheated to boiling. Sections were incubated for 30 min in a 10% normal goat serum/phosphate-buffered saline solution to block nonspecific antibody binding. Tissue sections were incubated with rabbit anti-mouse polyclonal antibody raised against 3-NT (1:200 dilution, Upstate Biotechnology, Lake Placid, N.Y.) for 1 h. Biotinylated secondary anti-rabbit serum was then applied (1:200), followed by horseradish peroxidase complex reagent (ABC Elite, Vector Laboratories, Burlingame, Calif.). Positive immunoreactivity was visualized through the development of diaminobenzidine (DAB) chromogen. Harris’ modified hematoxylin was used for nuclear counterstaining. Preliminary experiments were conducted to verify the specificity of immunostaining in our laboratory. Preincubation of primary antibody with free 3-NT (1 mM) completely quenched positive tissue staining, whereas tyrosine (1 mM) had no effect. Nonimmune serum (isotypic) controls also showed no detectable immunoreactivity in any treatment group.

Digital image analysis
Images of immunostained tissue were captured using an Olympus microscope (BX-40) and a high-resolution digital camera (Pixera, Inc., 1260x960 pixel resolution). Unmodified images were analyzed using research-based image analysis software (ImagePro Plus, Media Cybernetics, Md.). Six endothelial regions of each aortic ring were systematically captured at 200x, representing ~45% of the total vascular endothelium circumference. Relative extent of 3-NT immunoreactivity was assessed using digital color image analysis. Similar to other reports (23) , we observed the most striking difference in ‘positive’ vs. background staining regions in the blue channel of RGB color profile (i.e., red, green, blue). There was a well-defined segmentation of the intensity profile such that brown DAB staining registers between 0 and 100 intensity units, whereas shades of blue or white background were consistently greater than 100 intensity units, as shown in Fig. 4 . For each vascular image, the percentage of positive pixels in the captured images was used as an objective and semi-quantitative measure of immunoreactivity (24) , allowing statistical comparisons among groups (25) . Intra-observer variability was consistently less than 12% (coefficients of variation from 3 daily measurements), whereas inter-observer variability was less than 10% (coefficients of variation of average measurements between three observers collecting six images on three different days).



View larger version (50K):
[in this window]
[in a new window]
 
Figure 4. Semi-quantitative digital image analysis method for rat aortic endothelial 3-nitrotyrosine immunoreactivity. Top and middle panels: representative photomicrographs of aortic endothelium from a vehicle-treated (top panel) and an ANG II-treated rat (middle panel) were captured as described in Materials and Methods (400x mag.). Tissue section immunostained with rabbit polyclonal 3-nitrotyrosine, demonstrating specific immunoreactivity of intimal layer (A) but not medial smooth muscle cells (B). Bottom panel: Example of pixel intensity distributions in the blue color channel representing regions delineated by boxes A (endothelium), B (smooth muscle), and C (endothelium). Color patterns for A and B are overlaid. Note the clear differentiation of frequency distributions between perceived ‘brown’ immunoreactive (A) and ‘blue’ counterstain (B and C). Extent of positive immunoreactivity was determined as frequency of pixels registering in the 0–100 range, as described in Materials and Methods.

Statistical analyses
All data are presented as mean ± SE. Statistical evaluations were performed using Sigmastat software (Jandel Scientific Inc., San Rafael, Calif.). Comparisons among treatment groups were performed using Student’s t tests or analysis of variance where appropriate (26) . Spearman nonparametric correlation analysis was used to test for significant association of functional and immunohistochemical data (26) . In all cases, P < 0.05 was deemed statistically significant.


   RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Figure 1 shows changes in plasma renin activity, hemodynamics, and cardiac mass after ANG II or vehicle infusion for 3 days. Statistically significant reductions in plasma renin activity were observed by day 3 after ANG II administration relative to vehicle infusion, illustrating hormonal feedback of the renin-angiotensin axis and demonstrating successful infusion of low-dose ANG II. There was no significant change in plasma aldosterone concentrations (data not shown). In contrast, ANG II did not cause significant changes in systolic blood pressure or heart rate by day 3 (Fig. 1) . Similarly, no significant change in body weight, total heart weight, or left ventricular weight (all parameters known to be affected at higher ANG II exposures) was observed by day 3. Aortic cross sectional areas were also unaffected by ANG II infusion (data not shown).



View larger version (34K):
[in this window]
[in a new window]
 
Figure 1. Plasma renin activity (PRA) and hemodynamic parameters measurement in saline control saline (vehicle, VEH) and angiotensin II (ANG II) infusion. Top, left panel: PRA was measured by radioimmunoassay at day 3 of infusion. Data are mean ± SE, n = 6–8. *P < 0.05. Top, middle and right panel: Systolic blood pressure was monitored using the tail-cuff method at day 0 and day 3 of infusion. Bottom panel: No significant change in body weight, heart weight, and left ventricle (LV) weight at day 3 of infusion (see text).

Isolated vascular contractile responses are shown in Fig. 2 . Maximal vascular contractile response to total depolarization (125 mM KCl) was not different between ANG II and vehicle-infused groups. Contractile responses to the {alpha}-receptor agonist phenylephrine were also unaltered (EC50 49±12 vs. 73±14 nM; Emax 1.09±0.06 vs. 0.99±0.06 g; ANG II vs. control, respectively). Contractile response to ANG II in vitro was not statistically affected by 3 day infusion (EC50 280±110 vs. 183±41 nM; Emax 0.41±0.12 vs. 0.34±0.8 g; ANG II infused vs. control, respectively).



View larger version (21K):
[in this window]
[in a new window]
 
Figure 2. Vascular contractile responses in isolated aortic rat rings. Left panel: maximal contractile responses were obtained by exposure of rings to a total depolarizing concentration of 125 mM KCl (n=6–8). Middle and right panels: concentration-response relationships for phenylephrine and angiotensin II (1 nM to 1 µM) in vessels obtained from ANG II (open circles) and vehicle-treated rats (filled circles). No differences in EC50 or Emax values were observed (see text).

Despite unaltered vascular contractile properties, significant alteration in acetylcholine-induced relaxation was observed (Fig. 3 ). A statistically significant sixfold reduction in EC50 (390±12 vs. 64±13 nM, ANG II infused vs. vehicle infused) was observed, with no change in maximal relaxant response (Emax 93±4 vs. 109±4). No significant differences in extent of phenylephrine-induced precontraction were observed among treatment groups.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 3. Vascular relaxation responses in isolated aortic rat rings. Top panel: change in vascular endothelium-dependent relaxation response to acetylcholine (ACH, 1 nM to 1 µM) obtained form ANG II (open circles) and vehicle-treated rats (filled circles); n = 6–8, EC50, P < 0.05. Relaxation responses were presented as percent relaxation of phenylephrine precontraction (80% maximum contraction), n = 6–8. Bottom panel: endothelium-independent relaxation response to nitric oxide donor sodium nitroprusside (SNP) was generated in the same manner as ACH (n=6–8).

In contrast to diminished acetylcholine responses, no significant change in vasorelaxant response to the endothelium independent and ‘spontaneous’ NO donor sodium nitroprusside was observed between treatments (Fig. 3 , EC50 1.11±0.3 nM vs. 0.84±0.2 nM; Emax 117±9 vs. 107±1; ANG II vs. vehicle, respectively).

Representative photomicrographs of vascular immunostaining for 3-NT are shown in Fig. 4 . Extensive protein nitration was observed in the vasculature from ANG II-treated animals and was found nearly exclusively in the intimal layer. In contrast, little evidence of 3-NT was found in control (vehicle infusion). Figure 4 also shows the distinct color distribution patterns for diaminobenzidine (positive signal for 3-NT immunohistochemistry) and hematoxylin counterstain. This distinction was used to determine the percentage of the cross sectional area considered a positive signal using digital image analysis (see Materials and Methods).

Digital image analysis demonstrated statistically significant increases in vascular 3-NT immunoprevalence from ANG II-treated animals relative to vehicle infusion controls (Fig. 4) . This difference was confined to the endothelial layer (no significant differences were observed when regions of exclusively vascular smooth muscle were compared; see Fig. 5 ). In addition to comparing the two treatment groups, controls were used to evaluate sensitivity and selectivity of the primary 3-NT antibody. The positive immunostaining signal could be completely abolished by preincubation of primary antibody with free nitrotyrosine in solution (1 mM) or by replacing it with preimmune serum. Significant 3-NT immunoprevalence was observed in the vehicle treatment group when compared to these staining controls, demonstrating a slight but detectable protein nitration (and corresponding peroxynitrite production) under control conditions (Fig. 5 , top panel).



View larger version (20K):
[in this window]
[in a new window]
 
Figure 5. Extent of 3-NT immunoreactivity in rat aortic endothelium and correlation to vascular function. Top panel: quantitative measure of aortic 3-NT immunoreactivity and isotypic staining controls from ANG II- (open bars) and vehicle-treated rats (filled bars). A rabbit, anti-mouse, polyclonal, 3-nitrotyrosine primary antibody was used to detect endothelial protein nitration. Preimmune rabbit IgG serum was used in place of the primary antibody for isotypic controls. {dagger}P < 0.05 for both treatment groups vs. isotype staining controls; {ddagger}P < 0.05 for ANG II treatment vs. vehicle, via one way ANOVA with SNK post-hoc. Bottom panel: significant positive correlation between aortic endothelial 3-NT immunoprevalence and endothelial-dependent relaxant responses. Data plotted as mean 3-NT immunoreactivity per rat (n=6 independent determinations) vs. mean EC50 values per rat (n=4–6 rings) from ANG II-treated (filled circles) and vehicle-treated (open circles) rats. P < 0.02 via Spearman’s nonparametric correlation analysis.

The relationship between the prevalence of endothelial protein nitration and endothelium-dependent functional response to acetylcholine is shown in Fig. 5 (bottom panel). Measurements of 3-NT immunoprevalence (using image analysis) and acetylcholine EC50 were related for each animal in the study. A highly statistically significant inverse correlation was observed between the extent of intimal protein nitration and endothelium-dependent acetylcholine functional response (P<0.02, Spearman nonparametric correlation analysis).


   DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
First identified as a potent vasoconstrictor in the 1950s, angiotensin II now represents a pivotal therapeutic target for the management of many forms of cardiovascular disease. For example, inhibition of ANG II formation (through the use of angiotensin converting enzyme inhibitors) or selective blockade of ANG II receptors have been shown to be valuable for the treatment of essential hypertension, congestive heart failure, and coronary artery disease (1 , 2) . Even though ANG II was first recognized as a vasoconstrictor, its roles are now known to be diverse, including stimulation of cardiac and vascular cell growth and division, and activation of vascular NADH/NADPH oxidase activity (1 2 3 4 5 6) . Given these diverse hormonal influences, the long-term value of ANG II inhibition for cardiovascular disease may be mediated by nonhemodynamic actions rather than acute vasorelaxant effects per se (2) .

The vascular endothelium plays a key role in the local regulation of vasomotor tone and prevention of thrombus formation. Using agents like acetylcholine or changes in flow to stimulate the release of NO (e.g., endothelium-derived relaxing factor, EDRF), clinical studies have demonstrated the importance of EDRF/NO in both basal and stimulated control of vascular tone (10 11 12) . Dysfunction of vascular endothelium (particularly decreased activity of NO-dependent pathways) has been associated with a wide array of cardiovascular risk factors including chronic smoking, hypercholesterolemia, hypertension, and chronic heart failure (10 11 12 , 27) . Loss of endothelial integrity is known to promote vascular remodeling and thrombus formation, to impair tissue perfusion (particularly during stress), and to result in vasoconstriction (11) . Thus, endothelial dysfunction is associated with a diverse array of cardiovascular disease states and may be an important initiator of these progressive conditions. Inhibition of angiotensin-converting enzyme (ACE) has recently been shown improve endothelial function in patients with coronary artery disease or its risk factors (TREND; Trial on Reversing Endothelial Dysfunction). In this large-scale clinical trial, treatment with quinapril (an ACE inhibitor with affinity for vascular tissue) for 6 months was associated with a significantly improved vasodilator response to acetylcholine in coronary artery segments (28) . Similar improvements were also observed in microvasculature (29) . These clinical findings suggest that angiotensin has important influence on endothelium in vivo and that some benefit of ACE inhibitor therapy is mediated by improving endothelial function in vivo, but the mechanisms involved have not been established.

Recent studies have demonstrated that ANG II is an activator of superoxide production in several cell types, including fibroblasts (30) , mesangial cells (31) , and endothelial cells (32) . This stimulation is apparently mediated by the AT 1 receptor subtype activation, leading to increased gene expression of NADH/NADPH oxidase subunits p67phox (33) , p22phox (34) , and perhaps others. The role of this enhanced oxidase expression in ANG II-mediated actions is not clear but it may contribute to the other known cellular responses (e.g., proliferation, hypertrophy, etc.). Whereas isolated endothelial cell studies have demonstrated the selective presence of AT1 receptors (and an apparent absence of the AT 2 subtype) (32) , whether the endothelium plays a direct role in ANG II-related cardiovascular disease in vivo has not been established. Given previous reports of ANG II promotion of vascular superoxide formation and the newly recognized importance of endothelial NO for vascular health, we hypothesized here that ANG II in vivo would selectively modify endothelium-dependent function. Recent investigations have demonstrated that the biological activities of NO are highly dependent on both production- and destruction-related pathways (13) . A chemical pathway of biological importance appears to be the formation of peroxynitrite through the interaction of NO with superoxide anion. This reaction is exceedingly rapid and efficient (1.9x1010 M-1s-1; see ref 19 ), leading to reduced levels of available NO and formation of a highly reactive oxidant in vivo (17 18 19) . Peroxynitrite and related species aggressively nitrate protein tyrosine residues, leading to the chemically stable biomarker 3-NT (16) . We and others have demonstrated the value of this marker as evidence of NO dysregulation in disease, including advanced atherosclerotic lesions (35) , sepsis-related organ failure (36) , renal transplant rejection (37) , and others.

The ANG II infusion used in our studies (200 ng·kg-1·min-1) caused significant inhibition of plasma renin activity but no change in systemic blood pressure or cardiac mass on day 3. This dosing strategy appears to be physiologically relevant since it has been shown to produce steady-state ANG II blood levels similar to those observed in hypertensive animals and humans (~100 pg/ml) (38) . This strategy of a short-term, ‘slow pressor dose’ administration allowed us to evaluate early vascular changes during ANG II elevations in the absence of detectable cell growth or hemodynamic influences. No significant change in vascular response was observed for total depolarized contraction, {alpha}-adrenergic stimulation, or ANG II contractions. Using an identical animal model but more prolonged ANG II dosing [120 ng/(min·kg of 21 days)], Dowell et al. (39) observed significant potentiation of adrenergic contractile activities, likely due to increased vascular smooth muscle cell growth over 3 wk. In contrast, we observed significant reduction in acetylcholine-induced vasorelaxation prior to any changes in contractile responses and after only 3 days of elevated blood ANG II. This endothelium-dependent relaxant response is mediated by NO formation from the constitutively expressed nitric oxide synthase within endothelial cells (NOS III) (10) . Once formed, endothelium-derived NO apparently diffuses to vascular smooth muscle cells and elicits relaxation via cyclic GMP-dependent pathways (22) . In contrast to diminished acetylcholine response, no change in nitroprusside action was found. Nitroprusside is an exogenous agent that generates NO through nonenzymatic and enzymatic pathways in smooth muscle cells and does not require functional endothelium or NOS enzymes for activity. Since vascular smooth muscle response to an exogenous NO source (nitroprusside) was not altered, the diminished response to acetylcholine was apparently related to either decreased endothelial production of NO or reduced bioavailability to effector smooth muscle cells.

Consistent with selective endothelium dysfunction, we also observed intima-specific staining for protein 3-NT residues. Given the extremely rapid reaction rates for peroxynitrite formation from NO and superoxide (known to be diffusion rate limited) and from protein nitration, the staining pattern observed suggests that peroxynitrite was concentrated in or near the endothelial layer. In addition to serving as a biomarker of peroxynitrite, nitration of protein tyrosine residues is known to be an inhibitor of several biochemical pathways including mitochondrial respiration (40) , high-energy phosphate utilization (41) , prostaglandin synthesis (42) , and superoxide dismutase activity (43) . Peroxynitrite can also induce DNA strand breakage in human umbilical vein endothelial cells (44) . Thus, endothelial formation of peroxynitrite (through interaction of NO with superoxide) is likely to reduce availability of NO to vascular smooth muscle as well as have functional consequences to endothelial cell biochemistry. We recently reported a distinctly different vascular 3-NT staining pattern during development of organic nitrate pharmacodynamic tolerance (widespread distribution throughout smooth muscle) (45) . Thus, peroxynitrite formation and protein nitration may exist in a variety of vascular disorders, but the mechanisms involved and cellular distributions may be distinct and depend on the stimuli involved. While recent studies have suggested the existence of other potential biological pathways of tyrosine nitration, these studies have demonstrated that the chemistries responsible are dependent on neutrophil infiltration and activation (46 , 47) . Since we did not observe immune cell involvement in our vascular studies, the protein nitration observed here is most likely derived from ONOO- formation. In addition, previous studies demonstrate that cardiovascular tissue homogenates require exogenous addition of neutrophil myeloperoxidase (5 µM), 1 mM concentrations of nitrite and hydrogen peroxide, and long incubation times (>1 h) to produce detectable protein nitration (46) . In contrast, NO and superoxide anion are known to form OONO- at a diffusion-limited rate, even at very low concentrations. Under our experimental conditions, therefore, the observed protein nitration may be explained most simply by increased peroxynitrite formation rather than more complicated or less efficient chemical processes.

In summary, we found that low-dose and short-term administration of ANG II caused a selective reduction in endothelium-dependent (nitric oxide-mediated) relaxant effects. These changes occurred prior to any other established consequences of elevated ANG II in vivo, including enhanced vascular contractile responses, development hypertension, or increase in cardiac or vascular mass. Further evaluations revealed that this endothelial dysfunction was associated with increased production of peroxynitrite in vivo. Protein nitration in the endothelial layer correlated with the extent of functional impairment observed. Thus, selective perturbation of normal endothelial function is an apparent early or initiating event during ANG II exposure in vivo. Furthermore, vascular peroxynitrite formation (and attendant NO dysregulation) may mediate these early events during ANG II-induced vascular dysfunction in vivo. Our findings may help to explain the results of the recently published TREND trial (see above), and suggest that evaluation of selective endothelial therapies for the prevention of disease appears warranted.


   ACKNOWLEDGMENTS
 
This work was supported in part by grants from the American Heart Association, Ohio-West Virginia Affiliates, and the National Institutes of Health (HL59791 and HL63067).


   FOOTNOTES
 
Received for publication June 4, 1999. Revised for publication September 23, 1999.


   REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 

  1. Stroth, U., Unger, T. (1999) The renin-angiotensin system and its receptors. J. Cardiovasc. Pharmacol. 33 Suppl. 1,S21-S28
  2. Lonn, E. M., Yusuf, S., Jha, P., Montague, T. J., Teo, K. K., Benedict, C. R., Pitt, B. (1994) Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90,2056-2069[Medline]
  3. Brink, M., Wellen, J., Delafontaine, P. (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97,2509-2516[Medline]
  4. Griffin, S. A., Brown, W. C., MacPherson, F., McGrath, J. C., Wilson, V. G., Korsgaard, N., Mulvany, M. J., Lever, A. F. (1991) Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17,626-635[Abstract]
  5. Ratajska, A., Campbell, S. E., Cleutjens, J. P., Weber, K. T. (1994) Angiotensin II and structural remodeling of coronary vessels in rats. J. Lab. Clin. Med. 124,408-415[Medline]
  6. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., Alexander, R. W. (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74,1141-1148[Abstract]
  7. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K., Harrison, D. G. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97,1916-1923[Medline]
  8. Laursen, J. B., Rajagopalan, S., Galis, Z., Tarpey, M., Freeman, B. A., Harrison, D. G. (1997) Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95,588-593[Medline]
  9. Warnholtz, A., Nickenig, G., Schulz, E., Macharzina, R., Brasen, J. H., Skatchkov, M., Heitzer, T., Stasch, J. P., Griendling, K. K., Harrison, D. G., Bohm, M., Meinertz, T., Munzel, T. (1999) Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99,2027-2033[Medline]
  10. Britten, M. B., Zeiher, A. M., Schachinger, V. (1999) Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J. Int. Med. 245,315-327[Medline]
  11. Drexler, H., Hornig, B. (1999) Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 31,51-60[Medline]
  12. Panza, J. A. (1997) Endothelial dysfunction in essential hypertension. Clin. Cardiol. 20 Suppl. II,26-33
  13. Freeman, B. A. (1994) Free radical chemistry of nitric oxide. Chest 105,79S-83S
  14. Beckman, J. S., Crow, J. P. (1993) Pathological implications of NO, superoxide, and peroxynitrite formation. Biochem. Soc. Trans. 21,330-334[Medline]
  15. Pryor, W. A., Squadrito, G. l (1995) The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol. 268,L699-L722[Abstract/Free Full Text]
  16. Beckman, J. S. (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9,836-844[Medline]
  17. Beckman, J. S., Koppenol, W. H. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am. J. Physiol. 271,C1424-C1437[Abstract/Free Full Text]
  18. Huie, R. E., Padmaja, S. (1993) The reaction of NO with superoxide. Free Rad. Res. Commun. 18,195-199[Medline]
  19. Kissner, R., Nauser, T., Bugnon, P., Lye, P. G., Koppenol, W. H. (1997) Formation and properties of peroxynitrite studied by laser flash photolysis, high pressure stopped flow and pulse radiolysis. Chem. Res. Toxicol. 10,1285-1292[Medline]
  20. Bauer, J. A., Nolan, T., Fung, H.-L. (1997) Vascular and hemodynamic differences between organic nitrates and nitrites. J. Pharmacol. Exp. Ther. 280,326-331[Abstract/Free Full Text]
  21. Bauer, J. A., Fung, H.-L. (1991) Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 84,35-39[Medline]
  22. Bauer, J. A., Booth, B. P., Fung, H.-L. (1995) Nitric oxide donors: biochemical pharmacology and therapeutics in advances in pharmacology series. Ignarro, L. Murad, F. eds. Nitric Oxide: Biochemistry, Molecular Biology, and Therapeutic Implications ,361-381 Academic Press San Diego.
  23. Fritz, P., Wu, X., Tuczek, H., Multhaupt, H., Schwarzmann, P. (1995) Quantitation in immunohistochemistry. A research method or a diagnostic tool in surgical pathology? Pathologica 87,300
  24. Russ, J. C. (1998) Segmentation and thresholding. The Image Processing Handbook 3rd Ed ,371-430 CRC Press Boca Raton, Florida.
  25. Kuyatt, B. L., Reidy, C. A., Hui, K. Y., Jordan, W. H. (1993) Quantitation of smooth muscle proliferation in cultured aorta: a color image analysis method for the Macintosh. Anal. Quant. Cytol. Histol. 15,83-87[Medline]
  26. Zar, L. (1985) Biostatistical Analysis. 2nd Ed Prentice Hall Englewood Cliffs, N.J..
  27. Quyyumi, A. A., Dakak, N., Andrews, N. P., Hussain, S., Arora, S., Gilligan, D. M., Panza, J. A., Cannon, R. O., III (1995) Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J. Clin. Invest. 95,1747-1755
  28. Mancini, G. B. J., Henry, G. C., Macaya, C., O’Neill, B. J., Pucillo, A. L., Carere, R. G., Pepine, C. J., Pitt, B. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 94,258-265[Medline]
  29. Schlaifer, J. D., Wargovich, T. J., O’Neill, B., Mancini, G. B. J., Haber, H. E., Pitt, B., Pepine, C. J., . on behalf of the TREND investigators (1997) Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. Am. J. Cardiol. 80,1594-1597[Medline]
  30. Pagano, P. J., Clark, J. K., Cifuentes-Pagano, M. E., Clark, S. M., Callis, G. M., Quinn, M. T. (1997) Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. USA 94,14483-14488[Abstract/Free Full Text]
  31. Jaimes, E. A., Galceran, J. M., Raij, L. (1998) Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 54,775-784[Medline]
  32. Pueyo, M. E., Arnal, J. F., Rami, J., Michel, J. B. (1998) Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am. J. Physiol. 274,C214-C220[Abstract/Free Full Text]
  33. Pagano, P. J., Chanock, S. J., Siwik, D. A., Colucci, W. S., Clark, J. K. (1998) Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32,331-337[Abstract/Free Full Text]
  34. Marumo, T., Schini-Kerth, V. B., Brandes, R. P., Busse, R. (1998) Glucocorticoids inhibit superoxide anion production and p22 phox mRNA expression in human aortic smooth muscle cells. Hypertension 32,1083-1088[Abstract/Free Full Text]
  35. Beckman, J. S., Ye, Y. Z., Anderson, P., Chen, M. A., Accaviti, M. A., Tarpey, M. M., White, C. R. (1994) Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. 375,81-88
  36. Crouser, E. D., Julian, M. W., Dorinsky, P. M., Bauer, J. A. (1998) Endotoxin (LPS)-induced mitochondrial injury in the ileum correlates with nitric oxide (NO) dysregulation. Am. J. Respir. Crit. Care Med. 157,A104
  37. MacMillan-Crow, L. A., Crow, J. P., Kerby, J.D., Beckman, J. S., Thompson, J. A. (1996) Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc. Natl. Acad. Sci. USA 93,11853-11858[Abstract/Free Full Text]
  38. Tan, L. B., Jalil, J. E., Pick, R., Janicki, J. S., Weber, K. T. (1991) Cardiac myocyte necrosis induced by angiotensin II. Circ. Res. 69,1185-1195[Abstract]
  39. Dowell, F. J., Henrion, D., Benessiano, J., Poitevin, P., Levy, B. (1996) Chronic infusion of low-dose angiotensin II potentiates the adrenergic response in vivo. J. Hypertension 14,177-182[Medline]
  40. Brown, G. C. (1999) Nitric oxide and mitochondrial respiration Biochim. Biophys. Acta 1411,351-369[Medline]
  41. Mihm, M. J., Bauer, J. A. (1998) Peroxynitrite is a potent inhibitor of myofibrillar creatine kinase: implications in cardiac failure. Circulation 98,S362
  42. Zou, M., Martin, C., Ullrich, V. (1997) Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol. Chem. 378,707-713
  43. Yamakura, F., Taka, H., Fujimura, T., Murayama, K. (1998) Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J. Biol. Chem. 273,14085-14089[Abstract/Free Full Text]
  44. Szabo, C., Ohshima, H. (1997) DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1,373-385[Medline]
  45. Mihm, M. J., Coyle, C. M., Jing, L., Bauer, J. A. (1999) Vascular peroxynitrite formation during organic nitrate tolerance. J. Pharmacol. Exp. Ther. 291,350-354
  46. Sampson, J. B., Ye, Y., Rosen, H., Beckman, J. S. (1998) Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide. Arch. Biochem. Biophys. 356,207-213[Medline]
  47. Eiserich, J. P., Hristova, M., Cross, C. E., Jones, A. D., Freeman, B. A., Halliwell, B., van der Vliet, A. (1998) Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature (London) 391,393-397[Medline]



This article has been cited by other articles:


Home page
Toxicol SciHome page
O.-N. Bae, K.-M. Lim, J.-Y. Han, B.-I. Jung, J.-Y. Lee, J.-Y. Noh, S.-M. Chung, M.-Y. Lee, J.-Y. Lee, and J.-H. Chung
U-shaped Dose Response in Vasomotor Tone: A Mixed Result of Heterogenic Response of Multiple Cells to Xenobiotics
Toxicol. Sci., May 1, 2008; 103(1): 181 - 190.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G.-X. Zhang, X.-M. Lu, S. Kimura, and A. Nishiyama
Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation
Cardiovasc Res, November 1, 2007; 76(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Ding, A. Chapman, R. Boyd, and H. D. Wang
ERK activation contributes to regulation of spontaneous contractile tone via superoxide anion in isolated rat aorta of angiotensin II-induced hypertension
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2997 - H3005.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Girouard, L. Park, J. Anrather, P. Zhou, and C. Iadecola
Cerebrovascular Nitrosative Stress Mediates Neurovascular and Endothelial Dysfunction Induced by Angiotensin II
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 303 - 309.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. R. F. Nascimento, L. M. A. Lessa, M. R. Kerntopf, C. M. Sousa, R. S. Alves, M. G. R. Queiroz, J. Price, D. B. Heimark, J. Larner, X. Du, et al.
Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide
PNAS, January 3, 2006; 103(1): 218 - 223.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. S. Baliga, A. A. Chaves, L. Jing, L. W. Ayers, and J. A. Bauer
AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1373 - H1380.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. A. Masri, S. A. A. Comhair, T. Koeck, W. Xu, A. Janocha, S. Ghosh, R. A. Dweik, J. Golish, M. Kinter, D. J. Stuehr, et al.
Abnormalities in Nitric Oxide and Its Derivatives in Lung Cancer
Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 597 - 605.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. L. Oltman, L. J. Coppey, J. S. Gellett, E. P. Davidson, D. D. Lund, and M. A. Yorek
Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats
Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E113 - E122.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-J. Lee, K.-M. Kim, S. Namkoong, C.-K. Kim, Y.-C. Kang, H. Lee, K.-S. Ha, J.-A Han, H.-T. Chung, Y.-G. Kwon, et al.
Nitric Oxide Inhibition of Homocysteine-induced Human Endothelial Cell Apoptosis by Down-regulation of p53-dependent Noxa Expression through the Formation of S-Nitrosohomocysteine
J. Biol. Chem., February 18, 2005; 280(7): 5781 - 5788.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
R. Zhang, J. Ma, M. Xia, H. Zhu, and W. Ling
Mild Hyperhomocysteinemia Induced by Feeding Rats Diets Rich in Methionine or Deficient in Folate Promotes Early Atherosclerotic Inflammatory Processes
J. Nutr., April 1, 2004; 134(4): 825 - 830.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. C. Parkington, J. Dodd, S. E. Luff, K. Worthy, H. A. Coleman, M. Tare, W. P. Anderson, and A. J. Edgley
Selective Increase in Renal Arcuate Innervation Density and Neurogenic Constriction in Chronic Angiotensin II-Infused Rats
Hypertension, March 1, 2004; 43(3): 643 - 648.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. Rodrigo, W. Passalacqua, J. Araya, M. Orellana, and G. Rivera
Homocysteine and Essential Hypertension
J. Clin. Pharmacol., December 1, 2003; 43(12): 1299 - 1306.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. Wang, Y. Chen, T. Chabrashvili, S. Aslam, L. J. Borrego Conde, J. G. Umans, and C. S. Wilcox
Role of Oxidative Stress in Endothelial Dysfunction and Enhanced Responses to Angiotensin II of Afferent Arterioles from Rabbits Infused with Angiotensin II
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2783 - 2789.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. P. Didion and F. M. Faraci
Angiotensin II Produces Superoxide-Mediated Impairment of Endothelial Function in Cerebral Arterioles
Stroke, August 1, 2003; 34(8): 2038 - 2042.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Malo, F. Desjardins, J.-F. Tanguay, J.-C. Tardif, M. Carrier, and L. P. Perrault
Tetrahydrobiopterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model
Cardiovasc Res, August 1, 2003; 59(2): 501 - 511.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
V. Gerzanich, S. Ivanova, H. Zhou, and J. M. Simard
Mislocalization of eNOS and Upregulation of Cerebral Vascular Ca2+ Channel Activity in Angiotensin-Hypertension
Hypertension, May 1, 2003; 41(5): 1124 - 1130.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. W. E. Rush, J. R. Turk, and M. H. Laughlin
Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium
Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1378 - H1387.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Zhang, T. W. Hein, W. Wang, and L. Kuo
Divergent Roles of Angiotensin II AT1 and AT2 Receptors in Modulating Coronary Microvascular Function
Circ. Res., February 21, 2003; 92(3): 322 - 329.
[Abstract] [Full Text] [PDF]